At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
OMS721biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies
In Brief
A Phase 2 clinical trial evaluating OMS721 for Thrombotic Microangiopathies. Completed, enrolled 58 participants across 24 sites in 12 countries.
Detailed Summary
The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombotic Microangiopathies
CountriesBelgium, Bulgaria, Hong Kong, Italy, Lithuania, Malaysia, New Zealand, Poland, Singapore, Taiwan, Thailand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartNov 2014
Primary CompletionJan 2020
Study CompletionAug 2020
TodayJul 2026
First PostedAug 21, 2014
Enrollment StartNov 2, 2014
Primary CompletionJan 30, 2020
Study CompletionAug 11, 2020
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 11.9 years ago
Interventions
OMS721biological